Cresco Labs (FRA:6CQ) EBIT: €-31.4 Mil (TTM As of Mar. 2026)


FRA:6CQ Cresco Labs Inc FRA:6CQ
66 GF Score
Price €0.69
GF Value €0.88
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Cresco Labs EBIT?

Cresco Labs FRA:6CQ +6.77% 66 EBIT is €-31.4 Mil as of Mar. 2026. GuruFocus rates FRA:6CQ with a GF Score™ of 66/100 and a GF Value™ of €0.88 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Cresco Labs's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €10.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-31.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cresco Labs's annualized ROC % for the quarter that ended in Mar. 2026 was 4.16%. Cresco Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 9.03%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cresco Labs's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -4.66%.


Cresco Labs  (FRA:6CQ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cresco Labs's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=38.66 * ( 1 - 0% )/( (909.374 + 949.171)/ 2 )
=38.66/929.2725
=4.16 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1022.494 - 63.672 - ( 49.448 - max(0, 85.554 - 221.419+49.448))
=909.374

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Cresco Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=43.388/( ( (364.583 + max(106.108, 0)) + (369.506 + max(121.063, 0)) )/ 2 )
=43.388/( ( 470.691 + 490.569 )/ 2 )
=43.388/480.63
=9.03 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(32.355 + 84.261 + 55.355) - (63.672 + 2.191 + 0)
=106.108

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(32.997 + 93.801 + 58.594) - (59.864 + 4.465 + 0)
=121.063

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cresco Labs's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-31.404/674.145
=-4.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cresco Labs EBIT Related Terms


Cresco Labs EBIT Historical Data

* Premium members only.

The historical data trend for Cresco Labs's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cresco Labs EBIT Chart

Cresco Labs Annual Data
Trend Jan16 Jan17 Jan18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -181.05 -64.56 -76.37 44.80 -30.23

Cresco Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.64 14.43 4.40 -61.08 10.85

FRA:6CQ vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cresco Labs EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cresco Labs's EV-to-EBIT falls into.


FRA:6CQ
66GF Score
Cresco Labs Inc FRA:6CQ
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cresco Labs EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-31.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-31.4 Mil mean?
Cresco Labs (FRA:6CQ) has a EBIT of €-31.4 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cresco Labs.
Is Cresco Labs' EBIT too high?
Cresco Labs' current EBIT is €-31.4 Mil. Overall, Cresco Labs has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cresco Labs' EBIT compare to ZTS?
Cresco Labs' EBIT of €-31.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cresco Labs. Cresco Labs's current EBIT is €-31.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cresco Labs stock overvalued right now?
Based on GuruFocus' analysis, Cresco Labs (FRA:6CQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.88, compared to a current price of €0.69 — trading 21.1% below its estimated fair value. The current EBIT is €-31.4 Mil. Cresco Labs' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Cresco Labs (FRA:6CQ), the current EBIT is €-31.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cresco Labs (FRA:6CQ) Overvalued in 2026?

Based on GuruFocus' analysis, Cresco Labs stock appears to be undervalued. The current stock price of €0.69 is trading 21.1% below its estimated GF Value™ of €0.88. GuruFocus considers Cresco Labs to be Modestly Undervalued.

Key valuation signals for FRA:6CQ:

  • EBIT: €-31.4 Mil
  • GF Value™: €0.88 vs. price of €0.69 (21.1% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the FRA:6CQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cresco Labs Business Description

Address 600 W. Fulton Street, Suite 800, Chicago, IL, USA, 60661
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture, and sell retail and medical cannabis products through Sunnyside, Cresco Lab's national dispensary brand, and others. The company operates in one segment: the cultivation, manufacturing, distribution, and sale of cannabis. The company's brand includes: Cresco, High Supply, FloraCal Farms, Good News, Wonder Wellness Co., Mindy's, and Remedi.
66GF Score

Get the complete analysis for FRA:6CQ

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.69
Price
€0.88
GF Value